{
    "id": 14929,
    "fullName": "MYC positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MYC positive indicates the presence of the MYC gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4609,
        "geneSymbol": "MYC",
        "terms": [
            "MYC",
            "bHLHe39",
            "c-Myc",
            "MRTL",
            "MYCC"
        ]
    },
    "variant": "positive",
    "createDate": "12/08/2015",
    "updateDate": "08/28/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7160,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, INCB054329 inhibited Myc expression, induced apoptosis in multiple colorectal cancer cell lines in culture, and inhibited tumor growth in xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 3525).",
            "molecularProfile": {
                "id": 15187,
                "profileName": "MYC positive"
            },
            "therapy": {
                "id": 2812,
                "therapyName": "INCB054329",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6115,
                    "pubMedId": null,
                    "title": "The BET inhibitor INCB054329 is efficacious as a single agent or in combination with targeted agents in colorectal cancer models",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/3525.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19869,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCi975 treatment inhibited viability of a Myc-positive lymphoma cell line in culture (PMID: 31679823).",
            "molecularProfile": {
                "id": 15187,
                "profileName": "MYC positive"
            },
            "therapy": {
                "id": 9235,
                "therapyName": "MYCi975",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17557,
                    "pubMedId": 31679823,
                    "title": "Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31679823"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8563,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 reduced Myc expression in colorectal cancer cells in culture and resulted in moderate inhibition of tumor growth in cell ine xenograft models (PMID: 26983878).",
            "molecularProfile": {
                "id": 15187,
                "profileName": "MYC positive"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6688,
                    "pubMedId": 26983878,
                    "title": "Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26983878"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8355,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with CPI-0610 resulted in decreased expression of MYC and repression of tumor growth in acute myeloid leukemia xenograft models (PMID: 26815195).",
            "molecularProfile": {
                "id": 15187,
                "profileName": "MYC positive"
            },
            "therapy": {
                "id": 2033,
                "therapyName": "CPI-0610",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6629,
                    "pubMedId": 26815195,
                    "title": "Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26815195"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10683,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of JQ1 and Mekinist (trametinib) resulted in a synergistic effect, demonstrating decreased cell viability and reduced colony formation of MYC positive colorectal cancer cells in culture, and decreased tumor volume in cell line xenograft models (PMID: 27678457).",
            "molecularProfile": {
                "id": 15187,
                "profileName": "MYC positive"
            },
            "therapy": {
                "id": 5582,
                "therapyName": "JQ1 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8742,
                    "pubMedId": 27678457,
                    "title": "The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27678457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19868,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCi975 treatment inhibited colony formation in a Myc-positive prostate cancer cell line in culture, and inhibited tumor growth, and increased survival in a mouse model (PMID: 31679823).",
            "molecularProfile": {
                "id": 15187,
                "profileName": "MYC positive"
            },
            "therapy": {
                "id": 9235,
                "therapyName": "MYCi975",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17557,
                    "pubMedId": 31679823,
                    "title": "Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31679823"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9870,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, diffuse large B-cell lymphoma cell lines demonstrated sensitivity to GS-5829 treatment in culture, resulting in inhibition of cell growth, decreased Myc protein expression, and apoptotic activity (Blood 2016 128:5104).",
            "molecularProfile": {
                "id": 15187,
                "profileName": "MYC positive"
            },
            "therapy": {
                "id": 5276,
                "therapyName": "GS-5829",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7727,
                    "pubMedId": null,
                    "title": "Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines",
                    "url": "http://www.bloodjournal.org/content/128/22/5104?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7617,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 10058-F4 induced cell-cycle arrest and apoptosis and decreased Myc expression in ovarian carcinoma cell lines in culture, and inhibited proliferation of several Myc-positive patient-derived primary ovarian carcinoma cell cultures, with the level of sensitivity independent of the overall level of Myc expression (PMID: 25143136).",
            "molecularProfile": {
                "id": 15187,
                "profileName": "MYC positive"
            },
            "therapy": {
                "id": 3304,
                "therapyName": "10058-F4",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4130,
                    "pubMedId": 25143136,
                    "title": "Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25143136"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9012,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S63845 inhibited survival of several Myc-driven Burkitt lymphoma cell lines in culture (PMID: 27760111).",
            "molecularProfile": {
                "id": 15187,
                "profileName": "MYC positive"
            },
            "therapy": {
                "id": 4858,
                "therapyName": "S63845",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9013,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S63845 inhibited survival of Myc-driven mouse lymphoma cells in culture and in syngeneic animal models (PMID: 27760111).",
            "molecularProfile": {
                "id": 15187,
                "profileName": "MYC positive"
            },
            "therapy": {
                "id": 4858,
                "therapyName": "S63845",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7159,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, INCB054329 and a Jak1 inhibitor synergistically inhibited Myc expression, Stat3 phosphorylation, and cell proliferation of multiple myeloma cell lines in culture, and suppressed tumor growth in xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 692).",
            "molecularProfile": {
                "id": 24500,
                "profileName": "MYC pos STAT3 pos"
            },
            "therapy": {
                "id": 2812,
                "therapyName": "INCB054329",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6114,
                    "pubMedId": null,
                    "title": "The BET inhibitor INCB054329 is synergistic with JAK1 inhibition in models of multiple myeloma",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/692.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10685,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYC positive colorectal cancer cells harboring BRAF V600E demonstrated increased sensitivity to SCH772984 when treatment was combined with JQ1 in culture, resulting in decreased cell viability (PMID: 27678457).",
            "molecularProfile": {
                "id": 27726,
                "profileName": "BRAF V600E MYC pos"
            },
            "therapy": {
                "id": 5583,
                "therapyName": "JQ1 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8742,
                    "pubMedId": 27678457,
                    "title": "The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27678457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20317,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of JQ1 and Mekinist (trametinib) resulted in a response greater than either therapy alone in colorectal cancer cells expressing Myc and harboring KRAS G13D, demonstrating decreased cell viability (PMID: 27678457).",
            "molecularProfile": {
                "id": 27727,
                "profileName": "KRAS G13D MYC pos"
            },
            "therapy": {
                "id": 5582,
                "therapyName": "JQ1 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8742,
                    "pubMedId": 27678457,
                    "title": "The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27678457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10686,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYC positive colorectal cancer cells harboring BRAF A712T demonstrated increased sensitivity to SCH772984 when treatment was combined with JQ1 in culture, resulting in decreased cell viability (PMID: 27678457).",
            "molecularProfile": {
                "id": 27728,
                "profileName": "BRAF A712T MYC pos"
            },
            "therapy": {
                "id": 5585,
                "therapyName": "GSK525762 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8742,
                    "pubMedId": 27678457,
                    "title": "The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27678457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10684,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYC positive colorectal cancer cells harboring BRAF A712T demonstrated increased sensitivity to SCH772984 when treatment was combined with JQ1 in culture, resulting in decreased cell viability (PMID: 27678457).",
            "molecularProfile": {
                "id": 27728,
                "profileName": "BRAF A712T MYC pos"
            },
            "therapy": {
                "id": 5584,
                "therapyName": "JQ1 + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8742,
                    "pubMedId": 27678457,
                    "title": "The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27678457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 15187,
            "profileName": "MYC positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24500,
            "profileName": "MYC pos STAT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27726,
            "profileName": "BRAF V600E MYC pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27727,
            "profileName": "KRAS G13D MYC pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27728,
            "profileName": "BRAF A712T MYC pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27729,
            "profileName": "KRAS G12V MYC pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}